Norihiro Watanabe Selected Research

Immunotherapy

3/2024	Human platelet lysate enhances in vivo activity of CAR-Vδ2 T cells by reducing cellular senescence and apoptosis.
1/2021	Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
6/2011	Generation of antigen-specific cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells.
1/2008	Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma.
11/2007	Enhancement of anti-tumor cytotoxicity of expanded gammadelta T Cells by stimulation with monocyte-derived dendritic cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Norihiro Watanabe Research Topics

Disease

21	Neoplasms (Cancer) 03/2024 - 01/2007
6	Leukemia 01/2024 - 01/2008
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2024 - 01/2020
3	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2023 - 01/2008
2	Breast Neoplasms (Breast Cancer) 11/2021 - 10/2018
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018 - 01/2017
1	Aniridia 01/2023
1	Myeloid Leukemia (Leukemia, Myelocytic) 01/2023
1	Oliguria 09/2022
1	Hypotension (Low Blood Pressure) 09/2022
1	Acute Kidney Injury (Acute Renal Failure) 09/2022
1	Partial Epilepsies (Epilepsy, Partial) 09/2022
1	Poisoning 09/2022
1	Testicular Neoplasms (Testicular Cancer) 01/2020
1	Hemorrhage 01/2020
1	Hematologic Diseases (Blood Diseases) 10/2018
1	Head and Neck Neoplasms (Head and Neck Cancer) 11/2017
1	Virus Diseases (Viral Diseases) 06/2011
1	Residual Neoplasm 03/2011
1	Lymphoma (Lymphomas) 01/2008
1	Hematologic Neoplasms (Hematological Malignancy) 01/2008
1	Necrosis 01/2007
1	Carcinoma (Carcinomatosis) 01/2007

Drug/Important Bio-Agent (IBA)

14	Chimeric Antigen ReceptorsIBA 03/2024 - 01/2016
9	AntigensIBA 01/2023 - 01/2008
7	CytokinesIBA 01/2020 - 06/2014
4	Interleukin-4 (Interleukin 4)IBA 10/2018 - 06/2014
2	Cytokine Receptors (Cytokine Receptor)IBA 10/2018 - 06/2014
2	Interleukin-7 Receptors (Interleukin 7 Receptor)IBA 10/2018 - 06/2014
2	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 10/2018 - 06/2014
2	Neoplasm Antigens (Tumor Antigens)IBA 06/2014 - 03/2011
2	Peptides (Polypeptides)IBA 03/2011 - 04/2010
1	Bovine Serum AlbuminIBA 03/2024
1	Polysaccharides (Glycans)IBA 01/2023
1	LectinsIBA 01/2023
1	Levetiracetam (Keppra)FDA LinkGeneric 09/2022
1	CreatinineIBA 09/2022
1	Anticonvulsants (Antiepileptic Drugs)IBA 09/2022
1	Mucin-1 (CA 15-3 Antigen)IBA 11/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2021
1	LigandsIBA 11/2021
1	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 11/2021
1	2-toluenesulfonamide (OTS)IBA 03/2021
1	CyclinsIBA 01/2020
1	Cyclin A1IBA 01/2020
1	C-Type Lectins (C-Type Lectin)IBA 01/2020
1	Interleukin-13IBA 01/2018
1	Interleukin-10 (Interleukin 10)IBA 01/2018
1	InterleukinsIBA 06/2014
1	Messenger RNA (mRNA)IBA 01/2013
1	RNA (Ribonucleic Acid)IBA 01/2013
1	Indicators and Reagents (Reagents)IBA 01/2013
1	5- (2'- naphthyl)- 7- 4- chlorophenyl- (2,3,6,8- tetrahydro)pyrrolo- (3,4- e)(1,4)- diazepine- 6- thioxo- 8- (1H,7H)oneIBA 01/2008
1	Interleukin-2 (IL2)IBA 01/2008
1	HLA-DR Antigens (HLA-DR)IBA 01/2008
1	Zoledronic Acid (Zometa)FDA Link 01/2008
1	5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)IBA 11/2007
1	calcein AMIBA 11/2007
1	Ethidium (Ethidium Bromide)IBA 01/2007
1	ApigeninIBA 01/2007
1	FlavonoidsIBA 01/2007
1	Acridine OrangeIBA 01/2007
1	Radiation-Sensitizing AgentsIBA 01/2007

Therapy/Procedure

6	Therapeutics 01/2023 - 01/2016
5	Immunotherapy 03/2024 - 11/2007
2	Hematopoietic Stem Cell Transplantation 01/2023 - 01/2020
1	Stem Cell Transplantation 01/2024
1	Prostheses and Implants (Prosthesis) 01/2023
1	Renal Dialysis (Hemodialysis) 09/2022
1	Oncolytic Virotherapy 01/2021